Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 224

1.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Mar;120(6):612-620. doi: 10.1038/s41416-019-0389-6. Epub 2019 Feb 22.

PMID:
30792533
2.

The Molecular Diagnostics of Vascular Neoplasms.

Habeeb O, Rubin BP.

Surg Pathol Clin. 2019 Mar;12(1):35-49. doi: 10.1016/j.path.2018.10.002. Epub 2018 Dec 4. Review.

PMID:
30709447
3.

Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas.

Pareja F, Geyer FC, Brown DN, Sebastião APM, Gularte-Mérida R, Li A, Edelweiss M, Da Cruz Paula A, Selenica P, Wen HY, Jungbluth AA, Varga Z, Palazzo J, Rubin BP, Ellis IO, Brogi E, Rakha EA, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2019 Jan 18;5:6. doi: 10.1038/s41523-018-0101-7. eCollection 2019.

4.

A Case of Undifferentiated Sarcoma in the Superior Vena Cava and Bilateral Cervical Veins.

Kobayashi H, Kobayashi Y, Yuasa S, Okabe M, Yamada Y, Oda Y, Debiec-Rychter M, Rubin BP, Suzuki T.

Am J Case Rep. 2018 Dec 19;19:1507-1514. doi: 10.12659/AJCR.911659.

5.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
6.

Desmoplastic Small Round Cell Tumors With Atypical Presentations: A Report of 34 Cases.

Al-Ibraheemi A, Broehm C, Tanas MR, Horvai AE, Rubin BP, Cheah AL, Thway K, Fisher C, Bahrami A, Folpe AL, Fritchie KJ.

Int J Surg Pathol. 2019 May;27(3):236-243. doi: 10.1177/1066896918817140. Epub 2018 Dec 6.

PMID:
30522375
7.

Adult Primary Bone Sarcoma and Time to Treatment Initiation: An Analysis of the National Cancer Database.

Lawrenz JM, Curtis GL, Styron JF, George J, Anderson PM, Zahler S, Shepard DR, Rubin BP, Nystrom LM, Mesko NW.

Sarcoma. 2018 Nov 11;2018:1728302. doi: 10.1155/2018/1728302. eCollection 2018.

8.

Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.

Zhu G, Benayed R, Ho C, Mullaney K, Sukhadia P, Rios K, Berry R, Rubin BP, Nafa K, Wang L, Klimstra DS, Ladanyi M, Hameed MR.

Mod Pathol. 2018 Nov 21. doi: 10.1038/s41379-018-0175-7. [Epub ahead of print]

PMID:
30459475
9.

Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma.

Horvai A, Dashti NK, Rubin BP, Kilpatrick SE, Rudzinski ER, Lopez-Terrada D, Hubley MB, Davis JL, Fritchie K.

Mod Pathol. 2019 Feb;32(2):231-241. doi: 10.1038/s41379-018-0115-6. Epub 2018 Sep 11.

PMID:
30206413
10.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

Pareja F, Brandes AH, Basili T, Selenica P, Geyer FC, Fan D, Da Cruz Paula A, Kumar R, Brown DN, Gularte-Mérida R, Alemar B, Bi R, Lim RS, de Bruijn I, Fujisawa S, Gardner R, Feng E, Li A, da Silva EM, Lozada JR, Blecua P, Cohen-Gould L, Jungbluth AA, Rakha EA, Ellis IO, Edelweiss MIA, Palazzo J, Norton L, Hollmann T, Edelweiss M, Rubin BP, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 Aug 30;9(1):3533. doi: 10.1038/s41467-018-05886-y.

11.

EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms.

Michal M, Berry RS, Rubin BP, Kilpatrick SE, Agaimy A, Kazakov DV, Steiner P, Ptakova N, Martinek P, Hadravsky L, Michalova K, Szep Z, Michal M.

Am J Surg Pathol. 2018 Oct;42(10):1325-1333. doi: 10.1097/PAS.0000000000001109.

PMID:
29957732
12.

Quantification of fat content in lipid-rich myxoid liposarcomas with MRI: a single-center experience with survival analysis.

Kuyumcu G, Rubin BP, Bullen J, Ilaslan H.

Skeletal Radiol. 2018 Oct;47(10):1411-1417. doi: 10.1007/s00256-018-2974-9. Epub 2018 Jun 8.

PMID:
29948035
13.

ALK Expression in Angiomatoid Fibrous Histiocytoma: A Potential Diagnostic Pitfall.

Cheah AL, Zou Y, Lanigan C, Billings SD, Rubin BP, Hornick JL, Goldblum JR.

Am J Surg Pathol. 2019 Jan;43(1):93-101. doi: 10.1097/PAS.0000000000001103.

PMID:
29877921
14.

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, Edelweiss M, Wen HC, Piscuoglio S, Schultheis AM, Martelotto LG, Pareja F, Kumar R, Brandes A, Fan D, Basili T, Da Cruz Paula A, Lozada JR, Blecua P, Muenst S, Jungbluth AA, Foschini MP, Wen HY, Brogi E, Palazzo J, Rubin BP, Ng CKY, Norton L, Varga Z, Ellis IO, Rakha EA, Chandarlapaty S, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 May 8;9(1):1816. doi: 10.1038/s41467-018-04128-5.

15.

Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC.

Nat Med. 2018 Apr 10;24(4):525. doi: 10.1038/nm0418-525c.

PMID:
29634688
16.

Superficial Solitary Fibrous Tumor: A Series of 26 Cases.

Feasel P, Al-Ibraheemi A, Fritchie K, Zreik RT, Wang WL, Demicco E, Saeb-Lima M, Goldblum JR, Rubin BP, McKenney JK, Ko JS, Billings SD.

Am J Surg Pathol. 2018 Jun;42(6):778-785. doi: 10.1097/PAS.0000000000001027.

PMID:
29438169
17.

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC.

Nat Med. 2018 Feb;24(2):176-185. doi: 10.1038/nm.4475. Epub 2018 Jan 15. Erratum in: Nat Med. 2018 Apr 10;24(4):525.

18.

Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.

Lowery CD, Blosser W, Dowless M, Knoche S, Stephens J, Li H, Surguladze D, Loizos N, Luffer-Atlas D, Oakley GJ 3rd, Guo Q, Iyer S, Rubin BP, Stancato L.

Clin Cancer Res. 2018 Feb 15;24(4):847-857. doi: 10.1158/1078-0432.CCR-17-1258. Epub 2017 Nov 30.

19.

Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network.

Cell. 2017 Nov 2;171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014.

20.

Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant.

Perry KD, Al-Lbraheemi A, Rubin BP, Jen J, Ren H, Jang JS, Nair A, Davila J, Pambuccian S, Horvai A, Sukov W, Tazelaar HD, Folpe AL.

Mod Pathol. 2017 Oct;30(10):1512. doi: 10.1038/modpathol.2017.116.

Supplemental Content

Loading ...
Support Center